Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06820177 · ClinicalTrials.gov registry record · Phase 4
Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes
A Phase 4 study of Hemorrhage and Blood Loss, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 276
- Enrollment target
- 2
- Study locations
NCT06820177: Recruiting Phase 4 study of Hemorrhage and Blood Loss, sponsored by University of California, San Diego.
NCT06820177 is a Phase 4 study of Hemorrhage and Blood Loss that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 276 participants, roughly in line with the 253-participant average among 20 other Hemorrhage trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06820177, a Phase 4 study of Hemorrhage and Blood Loss, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 276 participants
- Enrollment target
- 2
- Study locations
Study Summary
Although procedural abortion in the second trimester is extremely safe, hemorrhage is one of the leading causes of morbidity and mortality. Tranexamic acid (TXA) is used commonly in obstetrics to prevent or manage intrapartum or postpartum hemorrhage and has been associated with decreased mortality and decreased blood loss at the time of birth. Some guidelines are recommending the use of TXA for both the prevention and management of bleeding for abortion care. However, there are currently no published studies assessing the association between TXA and bleeding outcomes for abortion procedures. This study will involve a randomized, placebo-controlled trial of pregnant patients aged 18 and older desiring dilation and evacuation (D\&E) for abortion or fetal demise at 18-24 weeks gestation. The primary aim is to determine whether prophylactic TXA has an effect on the need for additional interventions to control bleeding at the time of D\&E. The secondary aim is to determine whether prophylactic TXA has an effect on the mean quantitative procedural blood loss.
Primary Outcome
The use of any of the following interventions to manage excessive bleeding: at least one uterotonic medication given (i.e. methylergonovine maleate, carboprost tromethamine, misoprostol or additional oxytocin after the standard 30 units), blood transfusion, re-aspiration for bleeding or hematometra, intra-uterine balloon tamponade, uterine artery embolization, major surgery for bleeding, admission for bleeding, or prescription given for any uterotonic medication at discharge.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tranexamic Acid
Study Locations (2)
California
- University of California San Diego - San Diego
- Planned Parenthood of the Pacific Southwest - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2025-04-22 |
| Est. Completion | 2026-05 |
| Phase | Phase 4 |
What NCT06820177 shows while recruiting
NCT06820177 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 253-participant average among 20 other Hemorrhage trials with a reported enrollment target.
The record links to 5 conditions, with Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06820177 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06820177 about?
NCT06820177 is a clinical study titled "Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes". Although procedural abortion in the second trimester is extremely safe, hemorrhage is one of the leading causes of morbidity and mortality. Tranexamic acid (TXA) is used commonly in obstetrics to prevent or manage intrapartum or postpartum hemorrhage and has been associated with decreased mortality ...
What is the current status of trial NCT06820177?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 276 participants. The study started on 2025-04-22. Estimated completion is 2026-05.
What conditions does trial NCT06820177 study?
This clinical trial studies the following conditions: Hemorrhage, Blood Loss, Abortion, Dilation and Evacuation, Prophylactic Tranexamic Acid Use.
What interventions are being tested in trial NCT06820177?
The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT06820177?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06820177 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06820177's enrollment target sits among peer trials
276 6th of 20 higher than 15 of 20 other Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
RECRUITING · Phase 2
-
Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation
RECRUITING · Phase 2
-
NIRS Monitoring in Premature Infants
RECRUITING
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
-
The Effect of Fluids on Aortic VTI During C-section
RECRUITING
-
Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI